Company patents

Mirati Therapeutics, Inc.

MIRATI THERAPEUTICS, INC. demonstrates a strong and growing focus on core pharmaceutical innovation, with Pharmaceutical Preparations experiencing a remarkable 85.7% year-over-year growth in 2025 and comprising 54.8% of its portfolio. While Heterocyclic Compounds and Therapeutic Activity (Pharma) also show significant growth in 2025, the sharp decline in patent filings across most categories so far in 2026 (e.g., -68.2% for Heterocyclic Compounds) suggests a potential shift in strategy or a natural fluctuation given that 2026 data is partial.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

93 US filings (since 2023) · 7 categories · 9 themes

Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Heterocyclic Compounds (Pharma)Pharmaceutical PreparationsAcyclic / Carbocyclic Compounds
Who else files here? →
78since 2023
+45.5%YoY
Targeted Protein Degradation

Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.

Heterocyclic Compounds (Pharma)
Who else files here? →
35since 2023
+60.0%YoY
Advanced Cell & Gene Therapies

Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.

Pharmaceutical PreparationsPeptides & Proteins
Who else files here? →
32since 2023
+27.3%YoY
Immune Checkpoint Modulation

Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.

Therapeutic Activity (Pharma)
Who else files here? →
10since 2023
0.0%YoY
Targeted Drug Formulation Delivery

Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.

Pharmaceutical Preparations
Who else files here? →
5since 2023
-50.0%YoY
Nucleic Acid-Based Therapies

Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.

Pharmaceutical PreparationsTherapeutic Activity (Pharma)
Who else files here? →
4since 2023
+100.0%YoY
API Solid Form Engineering

Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.

Heterocyclic Compounds (Pharma)
Who else files here? →
2since 2023
0.0%YoY
Drug Candidate Synthesis

Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.

General Organic Chemistry Methods
Who else files here? →
2since 2023
0.0%YoY
Chemical Synthesis of Drug Intermediates

Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.

Heterocyclic Compounds (Pharma)
Who else files here? →
1since 2023
n/a

Patents

Showing 1-10 of 124

Page 1 of 13